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Summary
Objective: Recently, testican-1 has been described to be an inhibitor of MT1-MMP and MT3-MMP mediated pro-MMP-2 activation. As
MT1-MMP mediated pro-MMP-2 activation is of signiﬁcance for cartilage destruction in osteoarthritis, we studied the expression and
localization of testican-1 in human articular cartilage.
Methods: Cartilage samples from the medial and lateral tibia plateau were obtained from osteoarthritic patients who underwent joint
replacements, and were graded histomorphologically by Mankin score. Testican-1 expression was assessed in RNA isolated directly from
cartilage as well as in freshly isolated chondrocytes by reverse transcriptase-polymerase chain reaction (RT-PCR) and quantiﬁed by real-time
RT-PCR. Testican-1 protein was localized by immunohistochemistry in human osteoarthritic cartilage samples, in human fetal knee joint, and
in knees from mice.
Results: Testican-1 mRNA could be detected in cartilage and in freshly isolated chondrocytes both from moderately and from severely
damaged osteoarthritic cartilage. In the same donor, expression in chondrocytes from more severely affected regions was decreased
compared with chondrocytes from less affected regions. By immunolocalization, testican-1 protein could be detected in chondrocytes
predominantly of the superﬁcial and transitional zones. Matrix staining in these zones was greatly reduced in samples from more severely
affected osteoarthritic cartilage. A similar distribution was found in the articular cartilage of knees from 7-week-old mice. In addition to articular
cartilage, testican-1 was also present in growth plate cartilage.
Conclusions: Testican-1 is a component of cartilage, both of the joint and of the growth plate. Given its activity as an inhibitor of MT1-MMP
mediated pro-MMP-2 activation, it is reasonable to speculate that it participates in the regulation of matrix turnover in cartilage.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Testican-1 is a highly conserved chimeric proteoglycan
carrying both chondroitin sulfate and heparan sulfate
chains, initially characterized as the precursor of a seminal
plasma glycosaminoglycan-bearing peptide1,2. Due to the
modular organization of its core protein, encompassing four
osteonectin/SPARC-like domains, a Kazal-like motif and
a CWCV domain present in thyropin-type cysteine pro-
tease-inhibitors, it also has been called SPOCK3. Testican-
1 is differentially expressed in tissues, with highest
expression occurring in speciﬁc regions of the brain4,5.
Due to its expression by some, but not all, endothelial cells
it also can be found in several other tissues6,7. During the
past years, two structurally related proteins have been
identiﬁed, deﬁning a new family of modular proteogly-
cans8,9.
Recently, a regulatory activity of testican family members
on protease activities has been demonstrated. Whereas
both testican-1 and testican-3 inhibit activation of pro-MMP-2
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this inhibition of MT-MMPs9,10. Furthermore, testican-1
has been shown to inhibit the cysteine protease cathepsin
L11, and the heparan sulfate chains present on testican
may contribute to the regulation of the collagenolytic
activity of cathepsin K27. Therefore, it has been suggested
that testicans may regulate the degradation of extracel-
lular matrices10.
As progressive destruction of the cartilagenous matrix is
the morphological hallmark of osteoarthritis, we investigated
the expression of testicans by human chondrocytes.
Materials and methods
MATERIALS
Rabbit antiserum raised against the recombinantly ex-
pressed extracellular calcium-binding (EC) module of
human testican-1 was kindly provided by Dr Rupert Timpl,
Munich, who died unexpectedly last year. This antiserum
has been shown to stain a distinct band corresponding to
the core protein of testican-1 in immunoblots of several
human tissue extracts and shows no cross-reactivity with
human BM-40/osteonectin/SPARC12. Due to a 95% overall
amino acid identity between human and mouse testican-1,
cross-reactivity of this antiserum with mouse testican-1
could be anticipated3. The LSAB kit and 3-amino-9-ethyl-
carbazol were purchased from DAKO (Hamburg, Ger-
many).0
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Clostridium histolyticum, EC 3.4.24.3) were from Sigma
(Taufkirchen, Germany).
RNeasy Mini Kit, RNase-free DNase, Omniscript reverse
transcriptase and HotStarTaq DNA polymerase were from
Qiagen (Hilden, Germany), SYBR Green PCR Master Mix
was from Applied Biosystems (Darmstadt, Germany), the
pCR4-TOPO cloning vector was from Invitrogen (Karlsruhe,
Germany) and all primers were synthesized by MWG
Biotech (Munich, Germany) except for the random hex-
anucleotide primers which were from Roche Diagnostics
(Mannheim, Germany). All other chemicals used were of
analytical grade.
TISSUE SAMPLING
Human articular cartilage was obtained from the tibial
plateaus from 11 donors (aged from 47 to 79 years)
receiving a total knee replacement. Written, informed
consent was obtained from all the patients according to
the guidelines of the local ethics commission. Samples of
eight donors exhibiting differences in Mankin score of at
least 4 between cartilage from the lateral and medial tibia
plateau, respectively, were included in this study. After
a horizontal cut of the most proximal tibial bone, the tibial
plateau with cartilage and subchondral bone was removed
and split into a medial and a lateral part. Growth plate
cartilage from fetal knees were procured at autopsy from
fetuses from the 18th to the 25th gestational week that died
from diseases unrelated to the skeleton. These samples
were kindly provided by the Department of Pathology,
Augsburg, Germany.
TISSUE PROCESSING
Specimens for histomorphological examinations were
obtained from the immediate vicinity of the cartilage used
for the isolation of chondrocytes, and were ﬁxed in 4%
buffered formaldehyde for at least 72 h. After rinsing with
water, they were decalciﬁed in 10% EDTA solution, pH 7.4,
for up to 6 weeks. 3.5 mm sections were cut from parafﬁn-
embedded tissue, placed on glass slides pretreated with
silane, and routinely stained with hematoxylin/eosin and
safranin-O. All samples were classiﬁed histomorphologi-
cally using the grading system of Mankin13. To visualize the
distribution of sulfated glycosaminoglycans, occasionally
sections were stained with alcian blue at pH 1.0.
ISOLATION OF CHONDROCYTES
Cartilage samples were obtained from differently affected
regions of the lateral and medial tibial plateau, cut into small
pieces and washed with phosphate-buffered saline. After
sequential digestion with 0.2% pronase for 1 h and 0.025%
collagenase overnight, both in DMEM without addition of
fetal calf serum, the released chondrocytes were immedi-
ately used for RNA isolation.
Alternatively, RNA was isolated directly from cartilage
specimens as described by Gehrsitz et al.14.
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
Total RNA was extracted either directly from cartilage
specimens or from the chondrocytes immediately upon
release from the cartilage samples using the RNeasy
Mini Kit (Qiagen, Hilden, Germany), and digested withRNase-free DNase (Qiagen) to remove any contaminating
genomic DNA. cDNA synthesis from total RNA was per-
formed with Omniscript reverse transcriptase (Qiagen) using
(dT)15 (1 mM) and random hexanucleotide primers (5 mM;
Roche Diagnostics, Mannheim, Germany) simultaneously.
Aliquots of the cDNAs were incubated with HotStarTaq
DNA polymerase (Qiagen) and the following primers (each
at a ﬁnal concentration of 1 pM): for testican-1 (accession
XM_004038) 5#-AGA GTC ATC AAG CCC ACC AG-3# and
5#-AGA AAG CTT GCC ATC CTT GA-3# (product size
225 bp), for testican-2 (accession NM_014767) 5#-CGA
TGG CAA ACC AGA GAC TT-3# and 5#-TCC AGG AAG
AGG TCA GCA CT-3# (product size 222 bp), for testican-3
(accession NM_016950) 5#-GGA CTC ACT TGG CTG GAT
GT-3# and 5#-CAA GGT GGG TCT TGC TGT CT-3#
(product size 201 bp), for GAPDH (accession NM_002046)
5#-GAG TCC ACT GGC GTC TTC AC-3# and 5#-GGT GCT
AAG CAG TTG GTG GT-3# (product size 188 bp), and for
b-actin (accession NM_001101) 5#-TGG GAC GAC ATG
GAG AAA AT-3# and 5#-CAG AGG CGT ACA GGG ATA
GC-3# (product size 202 bp). The primer pairs for testican-1,
GAPDH and b-actin were designed to encompass at least
one intron in the genomic sequence to allow for discrimi-
nation of any sequences ampliﬁed from contaminating
genomic DNA. All primers were synthesized by MWG
Biotech (Munich, Germany) and were of high purity salt free
(HPSF)-quality. The polymerase was activated (15 min at
96(C) and then up to 40 cycles (45 s at 94(C, 45 s at 60(C,
45 s at 72(C) were performed on a RoboCycler Gradient 96
(Stratagene, Amsterdam, The Netherlands). The ampliﬁca-
tion products had the expected size and were veriﬁed by
cloning into the pCR4-TOPO vector (Invitrogen, Karlsruhe,
Germany) and subsequent sequencing. Ampliﬁcation prod-
ucts were visualized by agarose gel electrophoresis after
staining with ethidium bromide.
Fig. 1. Representative RT-PCR analysis of testican expression
using RNA obtained from freshly isolated chondrocytes (A) and
RNA directly isolated from cartilage specimens (B). Ampliﬁcation
products were separated on agarose gels and visualized after
staining with ethidium bromide. For control, ampliﬁcation reactions
were performed with 1 pg of the respective plasmid DNA (C).
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merase chain reaction (RT-PCR) was performed on an ABI
PRISM 7000 Sequence Detection System (Applied Bio-
systems) using the SYBR Green PCR Master Mix (Applied
Biosystems) and the following primers (each at a ﬁnal
concentration of 0.32 pM): for testican-1 5#-GTA AAA TGC
AGC CCT CAC AAA GT-3# and 5#-GCT TGC GGC TGACAC ACA-3# (product size 70 bp) and for GAPDH
(accession NM_002046) 5#-TGG TAT CGT GGA AGG
ACT CAT G-3# and 5#-TCT TCT GGG TGG CAG TGA
TG-3# (product size 56 bp). The ampliﬁcation products
obtained with these primers had the expected size and
were veriﬁed by cloning into the pCR4-TOPO vector
and subsequent sequencing. For real-time PCR, theFig. 2. Histochemical characterization of moderately (a,c,e) and severely (b,d,f) damaged osteoarthritic cartilage samples (barZ 500 mm).
Sections were stained with hematoxylin/eosin (a,b), safranin-O/fast green (c,d), and alcian blue at pH 1.0 (e,f), respectively. In the severely
damaged cartilage, deterioration of the surface and clustering of chondrocytes as well as loss of sulfated glycosaminoglycans is clearly visible.
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45 cycles (15 s at 95(C and 1 min at 60(C) were
performed. In each case, the correctness of the ampliﬁca-
tion products was controlled by determination of the
dissociation curves and by agarose gel electrophoreses.
Relative expressions were calculated using GAPDH as
reference gene.
IMMUNOHISTOCHEMISTRY
Deparafﬁnized samples were incubated for 4 min at
ambient temperature with 1 mg/ml pronase in 9 mM CaCl2,
pH 7.8, to improve immunoreactivity, rinsed with phos-
phate-buffered saline, and incubated for 15 min at ambient
temperature with 1% sodium azide to inactivate endoge-
nous peroxidase activity. After blocking nonspeciﬁc protein
binding sites with protein block solution (DAKO, Hamburg)
and with 10% normal goat serum, samples were incubated
with a rabbit antiserum (diluted 1:1000) raised against
testican-1 (kindly provided by Dr Rupert Timpl) for 2 h at37(C or overnight at 4(C. Bound antibody was visualized
using the LSAB kit (DAKO) and 3-amino-9-ethylcarbazol
(DAKO) as chromogen according to the instructions of the
manufacturer. As a negative control, sections were pro-
cessed for each sample in the absence of primary antibody.
Additionally, to demonstrate the speciﬁcity of the immu-
noreaction, antiserum was incubated with recombinantly
expressed EC module of testican-1 (kindly provided by Dr
Takako Sasaki) immobilized to polyvinylidene diﬂuoride
membrane (2 mg/cm2) prior to incubation of the samples.
Results
TESTICAN-1 IS EXPRESSED BY CHONDROCYTES FROM
HUMAN ARTICULAR CARTILAGE
In order to investigate whether human articular cartilage
chondrocytes express testican-1, mRNA was prepared
either from chondrocytes immediately after their isolation
or directly from the cartilage specimens and subjected to
RT-PCR using sequence speciﬁc primers. As can be seenFig. 3. Immunohistochemical localization of testican-1 in moderately (a,d) and severely (b,e) damaged osteoarthritic cartilage samples at the
surface (aec) and near the tide mark (def). Primary antibody was omitted in the negative controls (c,f). Chondrocytes of the superﬁcial and
transitional zones stain positive for testican-1, both in moderately and severely affected cartilage. In moderately damaged cartilage there is
strong matrix staining in the superﬁcial and transitional zone that is greatly reduced in the severely damaged cartilage. BarZ 100 mm.
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in the RNA obtained from freshly isolated chondrocytes (A)
and in RNA directly isolated from the cartilage specimens
(B). However, there appeared to be differences in quantity
between different donors and between different sampling
sites (not shown). In contrast, expression of testican-2 and
testican-3 was only barely, if at all, detectable.
To study whether osteoarthritic changes have an in-
ﬂuence on testican-1 expression, we compared by means
of real-time PCR expression in chondrocytes from the
medial and lateral tibia plateau of each donor individually to
compensate for interindividual differences. In ﬁve donors
with more severe changes on the medial tibia plateau
(difference in Mankin score of 5.8G 1.5), expression in
medial chondrocytes was reduced to 47G 29%, in three
donors with more severe changes on the lateral tibia
plateau (difference in Mankin score of 6.7G 1.5), expres-
sion in lateral chondrocytes was reduced to 26G 23%
(results given in meanGS.D.).
IMMUNOLOCALIZATION OF TESTICAN-1 IN HUMAN ARTICULAR
CARTILAGE
In order to localize testican-1 protein in human osteoar-
thritic cartilage, cartilage samples exhibiting moderate
Fig. 4. Immunohistochemical localization of testican-1 (a) in human
fetal knee at the articular surface. Primary antibody was omitted in
the negative control (b). There is a faint immunostaining of the
chondrocytes. BarZ 100 mm.[Fig. 2(a,c,e)] and severe [Fig. 2(b,d,f)] alterations, re-
spectively, were immunostained using an antiserum raised
against the recombinantly expressed EC module of human
testican-112. In moderately affected cartilage, there was
prominent cellular and matrix staining in the superﬁcial and
transitional zones [Fig. 3(a,d)]. In severely affected carti-
lage, clusters of chondrocytes in these superﬁcial zones
were positive for testican-1 too, but matrix staining was
strongly reduced [Fig. 3(b,e)].
In the fetal knee samples, there was a faint staining of
chondrocytes of the articular cartilage [Fig. 4(a)], but
testican-1 could be detected throughout the matrix down
to the growth plate [Fig. 5(a,c)], where proliferating cells
exhibited the strongest immunoreactivity. Staining intensity
of hypertrophic chondrocytes appeared to be reduced.
IMMUNOLOCALIZATION OF TESTICAN-1 IN CARTILAGE
FROM MICE
In order to get amore general idea of the signiﬁcance of the
occurrence of testican-1 in cartilage and to establish whether
mice could be used as a model for testican-1 deﬁciency and/
or overexpression, we prepared sections of knee joints from
7-week-old mice and immunostained them for testican-1. As
in the human joint, most intensive staining of chondrocytes
could be seen in the superﬁcial layer [Fig. 6(a)]. In the mouse,
too, testican-1 could also be detected in growth plate
cartilage where the proliferating columnar chondrocytes
exhibited the strongest immunoreactivity [Fig. 6(b)]. Addi-
tionally, there was also staining in the cartilagenous matrix of
the growth plate. Particularly, the staining intensity of the cells
was greatly reduced upon preadsorption of the antiserum on
immobilized testican-1 EC module.
Discussion
To the best of our knowledge we here describe for the
ﬁrst time that testican-1 is expressed by chondrocytes and
occurs in cartilage. So far this proteoglycan, that has initially
been identiﬁed as the progenitor of a seminal heparan/
chondroitin sulfate-bearing peptide1,2, has been described
to be expressed in speciﬁc regions of the brain4,5 as well as
by endothelial cells6, apart from its occurrence in testis. In
articular cartilage, we could detect testican-1 both in
individual chondrocytes and in clustering chondrocytes
present in more severely damaged osteoarthritic cartilage.
As can be expected for a secreted molecule, its distribution
was not restricted to the cells, but it was also a constituent
of the cartilagenous matrix, most prominently in the
superﬁcial and transitional zone. Both matrix staining and
expression were reduced in more severely damaged
osteoarthritic cartilage.
The presence of testican-1 was not limited to osteoar-
thritic articular cartilage. We could also detect testican-1 in
articular cartilage and growth plate cartilage of knees from
human fetuses and mice. In articular cartilage, chondro-
cytes positive for testican-1 were predominantly localized in
the superﬁcial and transitional zones. In growth plate
cartilage, there was prominent staining of the cartilagenous
matrix, and cellular staining appeared to be reduced in
hypertrophic chondrocytes.
At present, only speculations can be made with regard to
the functions of testican-1 in cartilage. One interesting
feature of this molecule is that it can carry heparan sulfate
chains. Though sulfated glycosaminoglycans are major
constituents of cartilage, these are predominantly of the
875Osteoarthritis and Cartilage Vol. 12, No. 11Fig. 5. Immunohistochemical localization of testican-1 (a,c) in human fetal knee near the growth plate. Primary antibody was omitted in the
negative controls (b,d). There is a faint staining of chondrocytes and a diffuse matrix staining, particularly in the zone of proliferating
chondrocytes. BarZ 100 mm.chondroitin sulfate and keratan sulfate type present on
aggrecan. Heparan sulfate chains, on the other hand, are of
particular interest due to their ability to bind to and modulate
the activities of numerous proteins, among them many of
the growth factors important for chondrocyte regulation15,16.
Indeed, perlecan, another heparan sulfate proteoglycan,
has recently been shown to be of great importance for
normal cartilage development17. Not only the activities of
growth factors but also of other proteins can be modulated
by interaction with glycosaminoglycans. An interesting
example with regard to cartilage is cathepsin K, that
contributes to the degradation of the superﬁcial gliding
surfaces of articular hyaline cartilage in osteoarthritis18.
Whereas glycosaminoglycans predominantly occurring in
cartilage, such as chondroitin sulfate and keratan sulfate,
enhance the collagenolytic activity of this degradative
enzyme, heparan sulfate selectively inhibits its activity19.
Given its preferential localization in the superﬁcial zones of
articular cartilage, testican-1 could well contribute to the
regulation of cathepsin K activity.The most important mediators of normal matrix turnover
and pathological matrix destruction in cartilage, however,
are the matrix metalloproteinases (MMPs)20,21. These zinc-
dependent neutral endopeptidases are synthesized as
inactive pro-enzymes, and both synthesis and activation
are strictly regulated. Once activated, MMP activity is
further regulated by the presence of tissue inhibitors of
metalloproteinases. One of the particularly interesting
enzymes in the context of cartilage matrix remodelling
and destruction is MMP-2 due to its wide substrate
speciﬁcity against cartilage matrix constituents, its expres-
sion in cartilage, and its upregulation in osteoarthritis22.
Furthermore, MMP-2 is an activator of pro-MMP-1323, the
enzyme responsible for most of the collagen degradation in
cartilage24. Activation of pro-MMP-2 in cartilage is achieved
by membrane-type 1 MMP (MT1-MMP)20, and this activa-
tion is sensitive to inhibition by testican-1 and testican-39.
Like testican-1, MT1-MMP predominantly localizes to
chondrocytes in the superﬁcial and transitional zones22. It
thus appears possible that one of the functions of testican-1
876 H-J. Hausser et al.: Testican-1 is expressed in cartilageFig. 6. Immunohistochemical localization of testican-1 (a,c) at the articular surface (a,b) and in the tibial growth plate (c,d) in the knee joint of
7-week-old mice. Primary antibody was omitted in the negative controls (b,d). At the articular surface, staining of the chondrocytes of the
superﬁcial zone can clearly be seen. In the growth plate, proliferating chondrocytes exhibit the strongest immunoreactivity. Due to incomplete
inhibition of endogenous peroxidase activity by the azide treatment, there is also unspeciﬁc staining of erythrocytes. BarZ 20 mm.in cartilage is being an inhibitor of an intricately regulated
activation cascade of degradative enzymes. Its apparent
reduction in hypertrophic chondrocytes of growth plate
cartilage would ﬁt with such a hypothesis, as it has been
shown recently that MT1-MMP deﬁciency is associated with
impaired endochondral ossiﬁcation25,26. Undoubtedly, the
functional signiﬁcance of testican-1 in cartilage deserves
further investigation.
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